Avidimer Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of targeted therapeutics to treat cancer and other diseases based on its patented, nano-scale dendrimer platform. Dendrimers are nano-scale, branch-like polymers which, when coupled with ligands, avidly target diseased cells and, when coupled with therapeutics, have the potential to treat cancer and other diseases more safely, effectively and completely than current therapeutics. Founded as a spinout from the University of Michigan Nanotechnology Institute for Medicine and Biological Sciences, the company’s initial product candidate, ATI-001, is expected to enter human clinical trials in the first half of 2006. Flagship General Partner Jim Matheson has been intimately involved during the Company’s founding and is currently a board member.

www.avidimer.com